Beyond Basic Beta Content Hub Write a Prescription for Pharma Dividends With PPH By Tom LydonDecember 9, 2021
Beyond Basic Beta Content Hub Omicron Variant Could Be Potent for Pharma Stocks, ETFs By Tom LydonDecember 2, 2021
Beyond Basic Beta Content Hub PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth By Tom LydonNovember 9, 2021
Beyond Basic Beta Content Hub Strong Vaccine Demand Lifting Pharma Sales By Tom LydonSeptember 2, 2021
Beyond Basic Beta Content Hub Alzheimer’s Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight By Tom LydonAugust 5, 2021
Beyond Basic Beta Content Hub Artificial Intelligence Set to Transform the Pharmaceutical Industry By Ben HernandezJune 1, 2021
Beyond Basic Beta Content Hub Pharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More Advances By Ben HernandezMarch 4, 2021
Nasdaq Investment Intelligence Content Hub Beyond the Vaccine: The Long Runway for Health and Pharmaceutical ETFs By Tom LydonNovember 25, 2020
Nasdaq Investment Intelligence Content Hub Some Good Deals Are Available in Pharmaceuticals ETFs By Tom LydonSeptember 15, 2020
Beyond Basic Beta Content Hub Assessing Political Outcomes for Pharmaceuticals ETFs By Tom LydonJuly 21, 2020
Beyond Basic Beta Content Hub Expect Pharmaceuticals M&A Activity to Rebound After COVID-19 Eases By Tom LydonApril 17, 2020
Beyond Basic Beta Content Hub Pharma ETFs Boosted After Senate Rejects House Drug Pricing Plan By Todd ShriberSeptember 23, 2019
Beyond Basic Beta Content Hub 8 ETFs to Capture Opportunities in Healthcare Sector By Max ChenAugust 22, 2019
Innovative ETFs Content Hub AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs By Max ChenJune 25, 2019
